The Taizhou Science and Technology Bureau recently announced proposed construction projects for key municipal laboratories in 2025, with five to settle in the Taizhou Medical High-tech Zone, located in Taizhou city, East China's Jiangsu province.
Key laboratories are important components of the scientific and technological innovation platform system. They serve as important bases for conducting high-level basic research, applied basic research and cutting-edge technology research.
A sunset view of the Taizhou Medical High-tech Zone. [Photo/WeChat account: weigg6666]
They include the Taizhou Key Laboratory of Large-scale Preparation of Antibody Drugs operated by Taizhou Mabtech Pharmaceutical, the Taizhou Key Laboratory of Early Antibody Development operated by Jiangsu Baiying Biotechnology and Taizhou Key Laboratory of Preparation and Evaluation of Intravenous Emulsion operated by Jiangsu Yingke Biopharmaceutical.
Then there is the Taizhou Key Laboratory of Vaccine Industrialization Development operated by Taizhou Pharmaceutical Industry Research Institute of Nanjing Medical University, as well as the Taizhou Key Laboratory of Target Discovery and Validation of New Drugs being operated by the Peking University Health Science Center (Taizhou) Medical and Health Industry Innovation Center.
During the construction period, the total estimated investment for the five laboratories will be 778 million yuan ($107.56 million).
Currently, the zone is home to one national key laboratory and 19 municipal key laboratories, including 13 approved for construction since 2024.